Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.63 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.62 |
| ▸ | NPY1R | P25929 | 2/20 | 0.59 |
| ▸ | NPY2R | P49146 | 2/20 | 0.59 |
| ▸ | NPY4R | P50391 | 2/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579410 | 0.97 | GHSR (0.60) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL29550887 | 0.97 | IL23R (0.64) | GHSRIL23R | |
| SCHEMBL29550921 | 0.97 | IL23R (0.64) | GHSRIL23R | |
| SCHEMBL31404052 | 0.95 | GHSR (0.68) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL29550452 | 0.94 | IL23R (0.61) | IL23R | |
| SCHEMBL29550445 | 0.94 | GHSR (0.59) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL29550903 | 0.94 | IL23R (0.62) | GHSRNPY1RNPY2RNPY4RIL23R | |
| SCHEMBL29551593 | 0.94 | IL23R (0.65) | GHSRKISS1RIL23R | |
| SCHEMBL29550696 | 0.94 | GHSR (0.67) | GHSRKISS1R | |
| SCHEMBL29391843 | 0.93 | IL23R (0.65) | GHSRNPY1RNPY2RNPY4RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | claimed |
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | GHSR 1/4885KISS1R 390/4885NPY1R 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.